NRX Pharmaceuticals, Inc. - Common Stock (NQ:NRXP)

2.409 +0.009 (+0.35%)

Delayed Quote Updated: 2:49 PM EDT, Oct 23, 2026 Add to My Watchlist

Price and Volume

Volume	638,046
Open	2.360
Bid (Size)	2.410 (900)
Ask (Size)	2.420 (1,800)
Prev. Close	2.400
Today's Range	2.240 - 2.415
52wk Range	1.620 - 5.055
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Final Step Completed for FDA Process Validation; Two-Year Stability for Preservative-Free Ketamine Treatment of Suicidal Depression by NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)

October 19, 2026

Via Get News

NRx Pharmaceuticals (Nasdaq:NRXP) Announces Completion of Manufacturing Process Validation and Two-Year Stability of Preservative-Free Ketamine

October 19, 2026

From NRx Pharmaceuticals, Inc.

Via GlobeNewswire

Performance

52-Week Range 52.4% below 52-week high

2.409

1.6252W Low 5.0552W High

1 Week 14.4% below 1-week high

2.361W Low 2.811W High

NRX Pharmaceuticals, Inc. - Common Stock (NRXP) traded between $1.62 and $5.05 over the past 52 weeks and last traded at $2.41, 52.4% below its 52-week high. Over the past week it ranged between $2.36 and $2.81.

Past 12 Months

-7.4%

-27.5%

-41.4%

-15.2%

-8.1%

-23.5%

1W -$0.19

1M -$0.91

3M -$1.70

6M -$0.43

YTD -$0.21

1Y -$0.74

NRXP was -23.5% over the past year, -15.2% over six months, -8.1% year to date, -7.4% in the last week.

12 Months vs Market

NRXP

-23.5%

DIA

+12.1%

SPY

+13.9%

QQQ

+16.5%

IWM

+13.3%

Over the past 12 months NRXP returned -23.5% versus DIA (Dow) +12.1%, SPY (S&P 500) +13.9%, QQQ (Nasdaq 100) +16.5% and IWM (Russell 2000) +13.3%.

Volume & Liquidity 0.72× 3-mo avg

Today 638,046 3-mo avg 880.8K

1.0M

729.0K

880.8K

1.0M

YTD

1.0M

937.2K

NRXP most recently traded 638,046 shares against a 3-month average daily volume of 880.8K.

More News

NRx Pharmaceuticals Announces Receipt of FDA Labeling Review Letter for Preservative-Free Ketamine

October 15, 2026

From NRx Pharmaceuticals, Inc.

Via GlobeNewswire

$11 Million Dollar Award for Robotic Magnetic Stimulation with Pharma Treatment for Resistant Depression Greatly Expands Application Potential for NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)

October 01, 2026

Via Get News

NRx Defense Systems, an NRx Company (Nasdaq:NRXP) Awarded $11 Million Dollar DARPA Prime Contract to Evaluate Robotic Magnetic Stimulation in conjunction with NRX-101 for Treatment of Resistant Depression

September 30, 2026

From NRx Pharmaceuticals, Inc.

Via GlobeNewswire

NRx Pharmaceuticals (Nasdaq: NRXP) Reports Update from the FDA Revising Previous Major Amendment to a Minor Amendment for Preservative-free Ketamine

September 15, 2026

From NRx Pharmaceuticals, Inc.

Via GlobeNewswire

First Interventional Psychiatry Use of FDA-Cleared Zeta TMS AI Driven Robotic System in Treatment of Suicidal Bipolar Depression by NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)

September 14, 2026

Via Get News

GeNeuro, Inc., an NRx Company (Nasdaq:NRXP) is awarded European Patent Rights for GNK-301, a novel drug candidate to treat Amyotrophic Lateral Sclerosis (ALS)

September 14, 2026

From NRx Pharmaceuticals, Inc.

Via GlobeNewswire

NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Begins Training and Deployment of Zeta Surgical's FDA-Cleared Robotic TMS System

September 11, 2026

From NRx Pharmaceuticals, Inc.

Via GlobeNewswire

NRx Pharmaceuticals to Participate in Upcoming Investor Conferences

September 08, 2026

From NRx Pharmaceuticals, Inc.

Via GlobeNewswire

FDA First Cycle Review of Preservative-Free Ketamine ANDA with No Drug Related Major Deficiencies Noted for Suicidal Bipolar Depression Treatment from NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)

August 20, 2026

Via Get News

NRX Pharmaceuticals Reports Q2 2026 Results: Full Earnings Call Transcript ↗

August 17, 2026

Via Benzinga

NRx Pharmaceuticals (Nasdaq:NRXP) Reports Second Quarter 2026 Financial Results and Provides Corporate Update; Conference Call to be Held on Monday, August 17th at 4:30pm ET

August 17, 2026

From NRx Pharmaceuticals, Inc.

Via GlobeNewswire

NRx Pharmaceuticals Nears FDA Decision on Preservative-Free Ketamine After Review Clears Hurdles ↗

August 10, 2026

Via MarketBeat

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Host Conference Call August 10 to Discuss FDA First-Cycle ANDA Review and Commercial Plans

August 07, 2026

From NRx Pharmaceuticals, Inc.

Via GlobeNewswire

FDA Completes First-Cycle Review of Preservative-Free Ketamine ANDA with No Drug Related Major Deficiencies; Final Packaging Certification Requested for Approval

August 07, 2026

From NRx Pharmaceuticals, Inc.

Via GlobeNewswire

First Patients Treated via FDA-Cleared Transcranial Magnetic Stimulation, Plus FDA Grant on D-Cycloserine-Based Drug for Depression: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)

June 29, 2026

Via Get News

New to The Street Announces Broadcast of Show #759 on Bloomberg Television Across the U.S., MENA and Latin America tonight 630pm est.

June 27, 2026

From New to The Street

Via ACCESS Newswire

NRx Pharmaceuticals Responds to Recent Public Statements Regarding Kadima Dispute

June 25, 2026

From NRx Pharmaceuticals, Inc.

Via GlobeNewswire

NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Treats First Patients Using Zeta Surgical's FDA-Cleared Zeta TMS Navigation System

June 25, 2026

From NRx Pharmaceuticals, Inc.

Via GlobeNewswire

NRx Pharmaceuticals Announces FDA Grant of Expanded Access Protocol for Use of D-Cycloserine-based NRX-101 for Augmentation of Transcranial Magnetic Stimulation in the Treatment of Depression

June 22, 2026

From NRx Pharmaceuticals, Inc.

Via GlobeNewswire

New to The Street broadcasts show #758 TODAY AT 6:30 PM ET on BLOOMBERG TELEVISION ACROSS THE UNITED STATES, LATIN AMERICA, AND MENA

June 20, 2026

From New to The Street

Via ACCESS Newswire

NRx Pharmaceuticals (Nasdaq:NRXP) notes presentation by Osmind, Inc. of IV Ketamine Efficacy vs. Nasal esketamine Efficacy at American Society of Clinical Psychopharmacology.

June 05, 2026

From NRx Pharmaceuticals, Inc.

Via GlobeNewswire

NRx Pharmaceuticals, Inc. Announces Closing of $22.3 Million Public Offering of Common Stock and Including Exercise of the Underwriters’ Option

June 04, 2026

From NRx Pharmaceuticals, Inc.

Via GlobeNewswire

These stocks are moving in today's pre-market session ↗

June 03, 2026

Via Chartmill

Frequently Asked Questions

Is NRX Pharmaceuticals, Inc. - Common Stock publicly traded?

Yes, NRX Pharmaceuticals, Inc. - Common Stock is publicly traded.

What exchange does NRX Pharmaceuticals, Inc. - Common Stock trade on?

NRX Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for NRX Pharmaceuticals, Inc. - Common Stock?

The ticker symbol for NRX Pharmaceuticals, Inc. - Common Stock is NRXP on the Nasdaq Stock Market

What is the current price of NRX Pharmaceuticals, Inc. - Common Stock?

The current price of NRX Pharmaceuticals, Inc. - Common Stock is 2.409

When was NRX Pharmaceuticals, Inc. - Common Stock last traded?

The last trade of NRX Pharmaceuticals, Inc. - Common Stock was at 10/23/26 02:49 PM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.